iShares MSCI Taiwan ETF vs Novavax Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.13 (market cap $12.74B), while Novavax Inc trades at $12.58 (market cap $1.82B). The key difference: iShares MSCI Taiwan ETF is far larger — about 7× Novavax Inc's market cap, and iShares MSCI Taiwan ETF is more actively traded (8,470,920 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Novavax Inc for 59 Days on average.
| EWT | NVAX | |
|---|---|---|
Market Cap | $12.74B | $1.82B |
Volume | 8,470,920 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $12.56 |
52-Week Low | $60.03 | $6.22 |
Typical Hold Time | 52 Days | 59 Days |
Enterprise Value | — | $1.39B |
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.01, down 1.92% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of its portfolio. Recent news highlights Taiwan's strategic importance in AI chip manufacturing and ongoing US-Taiwan economic cooperation, with Taiwanese companies planning $20 billion in US investments driven by AI demand (Reuters, 2026-09-02).
The outlook remains positive given Taiwan's central role in AI semiconductor supply chains, though geopolitical tensions with China present significant risks. Analyst sentiment is generally bullish with institutional investors increasing positions, including Bank of America's 22.4% stake increase in Q2 2026. Key support levels at $110-$112 provide downside protection while resistance sits at $115-$117.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →